Individuals with hereditary predispositions to cancer are at an increased risk to develop specific cancers compared to the general population. Next-generation sequencing (NGS) has allowed for the ability to analyze multiple genes simultaneously in 'panel' tests at a reduced cost compared to Sanger sequencing (1, 2) . Recently, we gained the ability to apply NGS technology to diagnose hereditary cancer syndromes accurately (3) . Two-tiered strategies for incorporating hereditary cancer panels into a testing algorithm have been proposed (4, 5) . This involves initial testing for genes with higher penetrance such as BRCA1/2 and reflexing to hereditary panels upon return of a negative results based on the level of risk and consideration of other syndromes (5) . As part of the early phase for the panel test offered by Myriad Genetics, select providers were given the opportunity to offer a single, multi-cancer gene panel test at no extra cost to patients meeting specific criteria for hereditary breast and colon cancer testing. Using these data, we assessed the benefits and limitations of single-tier hereditary cancer panel testing, compared to the previously proposed two-tiered approach (5) . The mutation rates, variant of undetermined significance (VUS) rates, and test costs were compared between the two approaches. (Fig. 1) . Following this 'single-tier' approach, a review was performed to determine deleterious mutation rates and VUSs rates. Ambry Genetics also provided their interpretations of the VUSs identified in these patients. The significance of the average differences in the number of VUSs between ancestry categories were evaluated using a one-way anova statistical test.
Using the data from the same patient cohort, mutation and VUS rates that would have resulted if the patient population had undergone a stricter, two-tiered approach were calculated based on the criteria originally proposed by Mauer et al. (Table S1 , Supporting Information) (5) .
We also compared the costs of the single-tier method to a two-tiered method. The client prices for various NGS cancer panels, BRCA gene testing, and Lynch syndrome gene testing were averaged. The prices from nine clinical labs were used to determine average cost per person of the single-tier and two-tiered methods.
Results
From September through November 2013, 468 patients were seen for genetic counseling (Fig. 1 ). Of these, 370 elected to proceed with genetic testing, and 318 Using the hereditary cancer panel as a single-tier test for individuals who met BRCA1/2 or Lynch syndrome testing criteria, seven individuals (6.7%) were reported to have a deleterious or suspected deleterious mutation. These were within APC, BRCA1/2, CHEK2, or EPCAM gene ( Table 1) . The seven mutation patients met NCCN guidelines for BRCA1/2 gene testing. One of these mutations (APC c.3920T>A) was classified as suspected deleterious.
We next analyzed our data using a two-tiered method (Table S1 ) in which the most likely hereditary cancer syndrome is tested first then reflexing to panel if no mutation was detected. Four (3.8%) of the seven mutations would have been detected (all BRCA1/2) ( Table 1) . Of the 105 patients examined, 32 patients would have been recommended for a second-tier, reflex panel test following the criteria from Mauer et al. (Table S1 ) (5) . No additional mutations would have been detected in the second tier in our cohort based on these criteria. The single-tier panel test approach increased our detection rate to 6.7% from 3.8% where three additional reported mutations (APC, CHEK2, and EPCAM), were detected. The family and medical history were not characteristic of the predicted phenotypes associated with these genes.
Using the single-tier approach, 74 unique VUSs were called by Myriad where each panel gene had a VUSs at least once in this cohort (Table S2) . We compared the interpretation of these variants with another laboratory, Ambry Genetics. Of the 74 VUSs found in the study, Ambry observed and interpreted 32 of them. Of these 32 VUSs, 17 (53%) were classified differently by Ambry ( (Table S3 ). The cost of the single-tier hereditary panel test was therefore 21% higher compared to the stricter two-tiered approach.
Discussion
As the cancer genetic community is moving to NGS panel testing, there are still many unanswered questions. By analyzing our cohort of patients that had initial panel testing against published two-tiered testing criteria, we found that more mutations would be found, but at a higher test cost. In addition, the types of mutations found were not always expected based on the family P o l y NBN c.37
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DM, deleterious/suspected deleterious mutation; NR, not reported; Poly = polymorphism; U = unknown; VLB = variant likely benign. a Intronic alterations beyond ± 5 are only reported by Ambry Genetics if they are pathogenic or likely pathogenic mutations. b reported as 'suspected deleterious'; test report describes 1.5-1.9-fold increased risk for colon cancer. c Reduced penetrance.
history and are not well-defined in terms of their clinical significance. In our population, we found an APC mutation (I1307K) in a male non-Jewish breast cancer patient, with a mother and grandfather with late onset colon cancer. Thus, the APC gene mutation could help to explain the colon cancer in his family and would not have been detected with two-tiered testing. Another woman with breast cancer at 39 was found to have a CHEK2 c.1555C>T mutation. Her father reportedly had colon cancer at age 46 and a maternal uncle had colon cancer at age 65. The patient did not meet previously proposed criteria (5) for two-tiered testing following negative BRCA1/2 gene testing, nor did she meet criteria previously outlined for CHEK2 gene testing (5) . The third mutation, EPCAM 3 ′ term del, was found in a 54-year-old unaffected female who had a family history of breast and ovarian cancer, but no colon cancer. This mutation was not expected based on the family history. It is possible that these patients had incorrectly documented their family histories (6) . Offering first-tier panel testing, which includes genes tertiary on the differential, could prevent inaccurate, or even limited, family histories from restricting testing options.
One of the unexpected findings in our study was the differences between labs' classifications of the 74 unique VUSs reported by Myriad. Of the 32 variants interpreted by both Ambry and Myriad, 17 (53%) were classified differently between the labs. Each lab has a different process for determining the significance of variants, and clinicians need to be aware of these inconsistencies. Sharing information on variant classifications will improve patient care by speeding up the VUSs reclassification process. Another challenge of panel testing is the high VUSs rate. Individuals of African American ancestry comprised 16.2% of our cohort and had a greater VUS frequency compared to those of other ancestries (p = 0.001).
Panel testing will certainly result in the detection of moderate penetrance genes, such as ATM and CHEK2. No consensus on recommendations for management or surveillance exists for lower-penetrant genes (3, 7), nor for individuals found to have multiple mutations of moderate penetrance (7) . There is also an issue of finding unexpected mutations, such as the EPCAM mutation in our cohort. Clinicians need to counsel patients about unexpected genetic findings or findings that may not affect the management. Of the seven initially reported deleterious mutation or suspected deleterious mutation carriers, six (5.7%) were clinically actionable. The remaining variant, APC c.3920T>A (I1307K) was reported as 'suspected deleterious' by Myriad Genetics with 'special interpretation' that indicated a lower penetrance than standard loss of function APC mutations. Literature review indicates controversy over whether this mutation is associated with a lower penetrance (1.5 to 1.9-fold increased non-polyposis colon cancer risk) (8) or no increased risk (9) , thus leading to different interpretations by different laboratories.
Single-tier panel test cost was on average $4099 per person, compared to $3392 per person for a two-tiered test. Thus, it was $707 more per person, or $74,235 altogether, to increase the detection rate by 2.9%, and to detect 75% more mutations in our cohort of 105 individuals. This is approximately the cost of treatment for one cancer. Although this is not a complete cost analysis, it appears that offering panel testing as a single-tier test would be cost-effective given the higher detection rate and the elimination of the costs associated with a return to clinic for further testing.
Conclusion
This is the first analysis that compares the outcomes of a single-tier, panel-only approach to the outcomes that would have resulted using a two-tiered approach. Use of a single-tier approach led to clinical reports of three deleterious mutations that would have otherwise gone undetected. There was also a higher VUSs rate in the single-tier approach. Similarly, both provider and patient should be aware of the potential to find lower-penetrant mutations for which management recommendations may or may not exist. There was also variability in the interpretation of VUSs and lower-penetrant genes between laboratories; data-sharing would help reduce these inconsistencies. The increased diagnosis rate with first-tier hereditary cancer panel testing suggests that this strategy should be discussed with all patients, as the benefits may outweigh the risks and costs for different patients.
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